Published in Drug Week, April 2nd, 2004
Previously presented data showed that among the patients receiving 0.3 mg of Macugen, 70% lost less than 3 lines of vision on the eye chart, compared with 55% of patients receiving sham injection, a 27% relative difference.
The new data suggest that the overall efficacy is independent of lesion size and patient age. Specifically, statistical interaction tests indicate efficacy is similar in small and large lesions (>4 Disc Areas vs....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week